Imaging Endpoints II
Imaging Endpoints II is recorded as a service provider in 28 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 28 trials · Latest update first
A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator’s Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients with Locally Advanced Head & Neck Squamous Cell Carcinoma
Sponsor Johnson & Johnson Enterprise Innovation Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)
Sponsor Corcept Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001).
Sponsor Loxo Oncology Inc.
- Start (EU)
- Latest update
- Estimated end
A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients with DLL3 Expressing Tumors Including Small Cell Lung Cancer
Sponsor Ideaya Biosciences Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Master Protocol for the Multi-Cohort, Phase 1/2 Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies
Sponsor Deciphera Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
An International, Phase 3, Randomized, Multicenter, Open-label Study of Ripretinib vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) with KIT Exon 11 and Co-occurring KIT Exons 17 and/or 18 Mutations Who Were Previously Treated with Imatinib (INSIGHT)
Sponsor Deciphera Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants with Relapsed/Refractory Primary Central Nervous System Lymphoma
Sponsor Deciphera Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate efficacy, safety, and tolerability of IMA203 versus investigator’s choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma (ACTengine® IMA203-301)
Sponsor Immatics US Inc.
- Start (EU)
- Latest update
- Estimated end
A multicentre, open-label, Phase 3, randomised controlled trial of duvelisib versus investigator’s choice of gemcitabine or bendamustine in patients with relapsed/refractory nodal T cell lymphoma with T follicular helper (TFH) phenotype (TERZO)
Sponsor Secura Bio Limited
- Start (EU)
- Latest update
- Estimated end
An Open-Label, Multi-Center, Phase Ib/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin (Plus A Single Pretreatment Dose of Obinutuzumab) in Adult Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Master Protocol for the Multi-cohort, Open-label, Phase 1/2 Study of DCC-3084 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Advanced Malignancies Driven by the MAPK Pathway
Sponsor Deciphera Pharmaceuticals Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 1/2, First in Human Study of DCC-3116 as Monotherapy and in Combination With RAS/MAPK Pathway Inhibitors in Patients With Advanced or Metastatic Solid Tumors With RAS/MAPK Pathway Mutations
Sponsor Deciphera Pharmaceuticals Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors
Sponsor Immunome Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF Class 1 and Class 2 alterations, in participants with cancer harboring BRAF alterations
Sponsor Fore Biotherapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment with a CDK4/6 Inhibitor
Sponsor Relay Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy
Sponsor Day One Biopharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2)
Sponsor Kite Pharma Inc.
- Start (EU)
- Latest update
- Estimated end
(20290) A Phase 1/2 Study of the Oral TRK Inhibitor Larotrectinib in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors
Sponsor Bayer Consumer Care AG
- Start (EU)
- Latest update
- Estimated end
Phase 1/2 study evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen as monotherapy or in combination with nivolumab in patients with recurrent and/or refractory solid tumors (ACTengine® IMA203-101)
Sponsor Immatics US Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator’s Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for Platinum-based Chemotherapy ineligible Elderly Patients with Locally Advanced Head & Neck Squamous Cell Carcinoma
Sponsor Nanobiotix
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Imaging Endpoints II?
The 2026-10-09 snapshot links Imaging Endpoints II to 28 distinct CTIS trials. Recorded services include Imaging, Central imaging, Central Imaging, Central imaging review, among 18 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Imaging Endpoints II?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Gastroenterology, Dermatology, Gynecology. Recorded phases include Phase 1, Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Imaging Endpoints II conducted?
The linked trials record locations in 20 countries, including Germany, France, Spain, Italy, Netherlands. These are trial locations, not confirmed office locations or countries where Imaging Endpoints II delivered services.
What can this page tell me about Imaging Endpoints II's trial experience?
Browse 28 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Imaging Endpoints II. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Imaging Endpoints II LLC